Research Project: Evaluating the clinical effectiveness of Hominax on improving sperm health in Australian men with mild to moderate infertility
The Max Biocare Institute has partnered with Western Sydney University’s National Institute of Complementary Medicine (NICM) to conduct an open label trial, to study the clinical effectiveness of Hominax on improving sperm health in men diagnosed with mild to moderate infertility.
Hominax is a TGA listed product consisting of 15 active ingredients, including antioxidants, herbs, nutrients and vitamins. Each active ingredient was selected specifically to improve sperm quality based on extensive scientific literature research. Hominax’s comprehensive formula will be clinically evaluated in a pre- and post-study consisting of 52 healthy men.
Healthy men aged between 20-60 years old, with mild to moderate infertility are being recruited at fertility clinics and hospitals around Australia. During the trial, each patient will be administered 2 capsules of Hominax on a daily basis for a period of 24 weeks. Semen quality will be measured before, during and after the treatment period. Semen quality will be measured by 3 parameters: concentration, motility and morphology. Results of the clinical trial will be published in leading scientific journals for the medical and science community.
To participate in this trial, please visit our information page.
This study is registered with the Australian New Zealand Clinical Trials Register.